Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IIB-III Efficacy Study of ABX203 Vaccine as an Adjunct Therapy to Nucleos(t)Ide Analogs to Maintain Control of HBV Replication After Cessation of Treatment in HBeAg Negative Patients With Chronic Hepatitis B

NCT02249988 is registered in ClinicalTrials.gov with Abivax S.A. as lead sponsor.

NCT NCT02249988
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02249988 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IIB-III Efficacy Study of ABX203 Vaccine as an Adjunct Therapy to Nucleos(t)Ide Analogs to Maintain Control of HBV Replication After Cessation of Treatment in HBeAg Negative Patients With Chronic Hepatitis B
Lead sponsor
Abivax S.A.
Phase
Phase 2/3
Overall status
Completed
Start date
December 31, 2014
Completion date
December 31, 2016
Enrollment
261 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis b